Table 1.
Detailed profile of the 38 patients with pituitary microadenomas and normal serum IGF-1 levels
| Patient number |
Sex | Age (years) |
BMI (kg/m2) |
MRI pituitary tumour size (mm) |
IGF-1 (nmol/l) |
IGF-1 SDS |
GH peak after GHRH–arginine (µg/l) |
Pituitary hormone deficits |
|---|---|---|---|---|---|---|---|---|
| 1 | F | 39 | 34·1 | 6 | 12·8 | −1·79 | 3·9 | TSH |
| 2 | F | 45 | 50·0 | 6 | 20·5 | −0·80 | 2·3 | TSH |
| 3 | F | 39 | 23·0 | 6 | 15·6 | −1·49 | 3·6 | TSH, ACTH, FSH, LH |
| 4 | F | 50 | 30·1 | 3 | 19·0 | −1·00 | 4·1 | None |
| 5 | F | 50 | 35·8 | 9 | 12·2 | −1·87 | 1·5 | TSH |
| 6 | F | 51 | 40·0 | 3 | 8·4 | −1·96 | 1·5 | TSH |
| 7 | F | 38 | 24·2 | 2·5 | 15·9 | −1·45 | 8·0 | TSH, FSH, LH |
| 8 | F | 53 | 23·8 | 2 | 11·0 | −1·60 | 16·0 | None |
| 9 | F | 59 | 32·5 | 3 | 13·1 | −1·31 | 6·0 | None |
| 10 | F | 35 | 23·2 | 4 | 16·2 | −1·42 | 32·0 | None |
| 11 | F | 38 | 31·6 | 4 | 20·8 | −0·93 | 5·5 | TSH, FSH, LH |
| 12 | F | 38 | 35·3 | 3 | 15·4 | −1·51 | 5·0 | None |
| 13 | F | 35 | 23·5 | 5 | 15·4 | −1·51 | 14·0 | TSH |
| 14 | F | 51 | 36·5 | 5 | 22·5 | 0 | 22·5 | None |
| 15 | F | 52 | 40·2 | 3 | 8·4 | −1·96 | 1·5 | None |
| 16 | F | 30 | 37·7 | 2 | 12·3 | −1·93 | 28·0 | TSH |
| 17 | F | 50 | 30·6 | 2·5 | 14·8 | −1·53 | 7·0 | None |
| 18 | F | 51 | 36·5 | 5 | 22·5 | 0 | 18·3 | None |
| 19 | F | 39 | 40·1 | 2 | 12·4 | −1·85 | 4·0 | None |
| 20 | F | 54 | 32·2 | 6 | 10·3 | −1·72 | 2·3 | None |
| 21 | F | 47 | 49·5 | 3 | 11·4 | −1·70 | 1·5 | TSH |
| 22 | F | 43 | 31·3 | 3 | 14·3 | −1·33 | 23·0 | TSH, FSH, LH |
| 23 | F | 52 | 51·3 | 5 | 10·5 | −1·69 | 3·6 | None |
| 24 | F | 54 | 34·5 | 2 | 13·1 | −1·16 | 4·9 | None |
| 25 | F | 56 | 32·7 | 5 | 11·1 | −1·39 | 14·3 | TSH |
| 26 | F | 53 | 38·4 | 2 | 16·5 | −0·48 | 3·7 | TSH |
| 27 | F | 50 | 39·3 | 2 | 14·0 | −1·19 | 3·0 | None |
| 28 | F | 30 | 28·1 | 6 | 19·9 | −0·83 | 21·6 | None |
| 29 | F | 57 | 22·7 | 2 | 12·3 | −1·14 | 52·5 | None |
| 30 | F | 44 | 26·0 | 4 | 14·8 | −1·23 | 36·3 | None |
| 31 | M | 39 | 24·1 | 4 | 14·4 | −1·87 | 2·3 | TSH, FSH, LH |
| 32 | M | 45 | 29·2 | 5 | 16·9 | −0·74 | 4·1 | TSH, FSH, LH |
| 33 | M | 50 | 19·7 | 3 | 11·8 | −1·67 | 5·4 | None |
| 34 | M | 42 | 36·3 | 7 | 12·0 | −1·73 | 7·1 | FSH, LH |
| 35 | M | 56 | 32·1 | 5 | 12·8 | −1·03 | 2·4 | FSH, LH |
| 36 | M | 33 | 42·1 | 6 | 14·0 | −1·69 | 2·7 | FSH, LH |
| 37 | M | 63 | 27·3 | 9 | 12·6 | −0·58 | 10 | FSH, LH |
| 38 | M | 30 | 42·1 | 4 | 12·4 | −1·91 | 1·8 | None |
| Mean ± SD | 45·8 ± 8·8 | 33·4 ± 7·9 | 4·2 ± 1·9 | 14·3 ± 3·5 | −1·34 ± 0·51 | 10·2 ± 11·6 |
TSH, thyroid-stimulating hormone; ACTH, adrenocorticotrophic hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; F, female; M, male. Peak GH responses in GH-deficient patients and partial GH-deficient patients are noted in bold and italics, respectively.